A Feasibility Randomised Placebo-controlled Trial With Objective Outcome Measures to Evaluate the Efficacy of Biosimilar Rituximab in Musculoskeletal and Mucocutaneous Systemic Lupus Erythematosus
Phase of Trial: Phase II
Latest Information Update: 02 May 2019
Price : $35 *
At a glance
- Drugs Rituximab (Primary) ; Methylprednisolone
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms ROOTS
- 30 Apr 2019 Planned End Date changed from 1 Dec 2019 to 1 Feb 2020.
- 30 Apr 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Feb 2020.
- 24 May 2017 Status changed from not yet recruiting to recruiting.